Gainers

• Codexis (NASDAQ:CDXS) shares rose 40.2% to $1.78 during Wednesday's after-market session. The market value of their outstanding shares is at $112.0 million. As per the press release, Q4 earnings came out today.
• Scienture Holdings (NASDAQ:SCNX) stock increased by 7.73% to $0.5. The company's market cap stands at $15.7 million.
• Nuwellis (NASDAQ:NUWE) shares increased by 6.66% to $1.44. The company's market cap stands at $1.1 million. As per the press release, Q4 earnings came out yesterday.
• Addex Therapeutics (NASDAQ:ADXN) shares moved upwards by 6.25% to $7.64.
• Precision Optics Corp (NASDAQ:POCI) stock moved upwards by 6.12% to $4.68. The market value of their outstanding shares is at $33.9 million.
• Iterum Therapeutics (NASDAQ:ITRM) shares rose 5.2% to $0.18. The market value of their outstanding shares is at $9.6 million.

Losers

• Kewaunee Scientific (NASDAQ:KEQU) shares declined by 12.2% to $36.0 during Wednesday's after-market session. The company's market cap stands at $120.5 million. As per the press release, Q3 earnings came out today.
• VSee Health (NASDAQ:VSEE) stock fell 9.17% to $0.26. The company's market cap stands at $10.7 million.
• Acurx Pharmaceuticals (NASDAQ:ACXP) shares fell 7.14% to $5.6. The company's market cap stands at $7.3 million.
• Traws Pharma (NASDAQ:TRAW) stock decreased by 7.04% to $1.85. The company's market cap stands at $13.8 million.
• Jin Medical International (NASDAQ:ZJYL) shares fell 6.54% to $0.13. The company's market cap stands at $22.2 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares decreased by 6.53% to $0.37. The market value of their outstanding shares is at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.